Wilson Yap, MD
Internal Medicine · Lakewood, NJNPI 1588638563
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $194 and has fallen 79.7% since, to $39 in 2025.
Across 47 payments — averaging $15.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$148
- Johnson & Johnson$88
- Philips North America LLC$74
- Daiichi Sankyo Inc.$65
- Novartis$59
- Exact Sciences$45
- plus $263 from 12 others
What the payments were for
- Food & beverage$741100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 10 | $148 |
| Johnson & Johnson | 6 | $88 |
| Philips North America LLC | 4 | $74 |
| Daiichi Sankyo Inc. | 4 | $65 |
| Novartis | 4 | $59 |
| Exact Sciences | 2 | $45 |
| Otsuka America Pharmaceutical, Inc. | 3 | $42 |
| Ultragenyx Pharmaceutical Inc. | 2 | $40 |
| Amgen | 2 | $30 |
| Pfizer | 2 | $28 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $16 |
| Merck | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $15 |
| AbbVie | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Sanofi Pasteur Inc. | 1 | $12 |
How this compares
$741 in reported general payments places this provider in the 60th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 60 | $55,237 |
| EliquisApixaban | 56 | $39,873 |
| OzempicSemaglutide | 19 | $26,188 |
| XareltoRivaroxaban | 15 | $21,699 |
| EntrestoSacubitril/Valsartan | 15 | $14,351 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $13,308 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $11,340 |
| RetacritEpoetin Alfa-Epbx | 39 | $4,631 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $4,299 |
| Atorvastatin Calcium | 298 | $3,135 |
| Cyclosporine | 11 | $2,443 |
| Divalproex Sodium | 34 | $1,888 |
| Duloxetine Hcl | 54 | $1,801 |
| Levothyroxine Sodium | 140 | $1,580 |
| Pantoprazole Sodium | 119 | $1,522 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $15 | $55,23760 claims |
| PfizerEliquis, Retacrit | $28 | $44,50595 claims |
| Novo NordiskOzempic | $148 | $26,18819 claims |
| Johnson & JohnsonXarelto | $88 | $21,69915 claims |
| NovartisEntresto | $59 | $14,35115 claims |
| AbbVieSynthroid | $14 | $56411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Lakewood
- Howard UdermanLakewood$955K
- Joseph MorelosLakewood$30K
- David ShulkinMorristown$1.7M
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.